ALPHA — Pharnext SCA Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -17527.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 2.69 | 0.25 | 0.04 | 0.08 | 0 | 1.85 | 8.95 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharnext SA is a France-based biopharmaceutical company. The Company is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The Company's prime focus is on neurodegenerative diseases and metabolic diseases.
Directors
- Elisabeth Svanberg CHM (61)
- David Solomon CEO (62)
- Philippe Pouletty CFD (64)
- Peter Collum CFO
- Xavier Paoli COO
- Daniel Cohen MDR
- Burkhard Blank OTH
- Adrian Hepner OTH
- Raj Thota OTH
- Pierre Bastid DRC
- Alexandre Berda DRC
- Kenneth Lee DRC
- Joshua Schafer DRC
- Lawrence Steinman DRC
- Piers Morgan NID (50)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- April 16th, 2007
- Public Since
- July 18th, 2016
- No. of Employees
- 44
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 78.19
- Address
- 14 rue de la Republique, SURESNES, 92150
- Web
- https://www.pharnext.com/fr/
- Phone
- +33 141092230
- Auditors
- KMPG
Upcoming Events for ALPHA
Similar to ALPHA
AB Science SA
Euronext - Paris
Advicenne SA
Euronext - Paris
Aelis Farma SA
Euronext - Paris
Boiron SA
Euronext - Paris
DBV Technologies SA
Euronext - Paris
FAQ
What is the Pharnext SCA share price?
As of Today at 21:37 UTC, shares in Pharnext SCA are trading at €0.00. This share price information is delayed by 15 minutes.
How has the Pharnext SCA share price performed this year?
Shares in Pharnext SCA last closed at €0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Pharnext SCA share price has underperformed the FTSE Global All Cap Index by -100% over the past year.
What are the analyst and broker recommendations for Pharnext SCA?
The overall consensus recommendation for Pharnext SCA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pharnext SCA dividend yield?
Pharnext SCA does not currently pay a dividend.
Does Pharnext SCA pay a dividend?
Pharnext SCA does not currently pay a dividend.
When does Pharnext SCA next pay dividends?
Pharnext SCA does not currently pay a dividend.
How do I buy Pharnext SCA shares?
To buy shares in Pharnext SCA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharnext SCA?
As of the previous close price of €0.00, shares in Pharnext SCA had a market capitalisation of .
Where are Pharnext SCA shares listed?
Here are the trading details for Pharnext SCA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALPHA
What kind of share is Pharnext SCA?
Based on an overall assessment of its quality, value and momentum Pharnext SCA is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharnext SCA share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Pharnext SCA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharnext SCA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -99.96%.
As of the last closing price of €0.00, shares in Pharnext SCA were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharnext SCA PE Ratio?
The Pharnext SCA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharnext SCA?
Pharnext SCA's management team is headed by:
- Elisabeth Svanberg - CHM
- David Solomon - CEO
- Philippe Pouletty - CFD
- Peter Collum - CFO
- Xavier Paoli - COO
- Daniel Cohen - MDR
- Burkhard Blank - OTH
- Adrian Hepner - OTH
- Raj Thota - OTH
- Pierre Bastid - DRC
- Alexandre Berda - DRC
- Kenneth Lee - DRC
- Joshua Schafer - DRC
- Lawrence Steinman - DRC
- Piers Morgan - NID